HARLEYSVILLE, Pa. (September 24, 2019) — Alliance Contract Pharma (ACP) announced today that the Company’s new $2 million Liquid Capsule filling line is fully operational. The new filling line significantly increases the Company’s manufacturing capacity and provides increased redundancy and flexibility for ACP clients.
HARLEYSVILLE, Pa. (January 22, 2019) — Alliance Contract Pharma (ACP) is pleased to announce that one of our clients has received FDA approval for the first twice-daily ocular corticosteroid indicated for the treatment of post-operative inflammation and pain following ocular surgery. This product represents a breakthrough in post-surgery care that can help increase the rate ...
Expertise, dedication, quality, cost effective and speed. In the health care industry, these values are commonly stated but not often achieved. Alliance Contract Pharma is a proven exception to the rule. Their steadfast commitment to each customer relationship is the reason drug developers engage ACP to solve problems and deliver innovative results.
The most common reason for producing sub-micron or nano-sized dispersions is to increase oral bioavailability of poorly soluble drugs. Other advantages include reduced fed/fasted variability, as well as faster onset of therapeutic action.